Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.32 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.30 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.30 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19615750 | 1.00 | SLC22A6 (0.36) | SLC22A6TP53MAPTSLC22A16CA2 | |
| SCHEMBL19615564 | 1.00 | SLC22A6 (0.36) | SLC22A6TP53MAPTSLC22A16CA2 | |
| SCHEMBL19615566 | 1.00 | SLC22A6 (0.36) | SLC22A6TP53MAPTSLC22A16CA2 | |
| SCHEMBL17281366 | 0.82 | GABRP (0.37) | SLC22A6GABRR1LMNACACNB3CACNA2D1 | |
| SCHEMBL8292735 | 0.80 | SLC22A6 (0.60) | SLC22A6TP53MAPTGABRR1LMNA | |
| SCHEMBL976030 | 0.80 | SLC22A6 (0.60) | SLC22A6TP53MAPTGABRR1LMNA | |
| SCHEMBL976447 | 0.80 | SLC22A6 (0.60) | SLC22A6TP53MAPTGABRR1LMNA | |
| SCHEMBL166411 | 0.79 | — | — | |
| SCHEMBL109971 | 0.79 | — | — | |
| SCHEMBL16059953 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3458584-B1 | FUSION PROTEINS COMPRISING AN ALDOLASE ENZYME JOINED TO A MALTOSE BINDING PROTEIN | CONSEJO SUPERIOR INVESTIGACION (ES) | 2021-07-07 | — | — | EP | disclosed |
| US-10683493-B2 | Fusion proteins comprising an aldolase enzyme joined to a maltose binding protein | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) | 2020-06-16 | — | — | US | disclosed |
| US-20190194638-A1 | FUSION PROTEINS COMPRISING AN ALDOLASE ENZYME JOINED TO A MALTOSE BINDING PROTEIN | TECHNICAL UNIVERSITY OF DARMSTADT (DE) | 2019-06-27 | — | — | US | disclosed |
| EP-3458584-A1 | FUSION PROTEINS COMPRISING AN ALDOLASE ENZYME JOINED TO A MALTOSE BINDING PROTEIN | Consejo Superior De Investigaciones Científicas (ES) | 2019-03-27 | — | — | EP | disclosed |
| WO-2017198717-A1 | FUSION PROTEINS COMPRISING AN ALDOLASE ENZYME JOINED TO A MALTOSE BINDING PROTEIN | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017198717-A1 | FUSION PROTEINS COMPRISING AN ALDOLASE ENZYME JOINED TO A MALTOSE BINDING PROTEIN | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) | 2017-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194638-A1 | FUSION PROTEINS COMPRISING AN ALDOLASE ENZYME JOINED TO A MALTOSE BINDING PROTEIN | ALDOA, TALDO1, DERA | SLC22A6 583/4885TP53 3562/4885MAPT 1406/4885 |
| US-10683493-B2 | Fusion proteins comprising an aldolase enzyme joined to a maltose binding protein | ALDOA, TALDO1, DERA | SLC22A6 583/4885TP53 3562/4885MAPT 1406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.